BEXSERO® is not expected to provide protection against all circulating meningococcal serogroup B strains and does not offer protection against strains A, C, Y, and W-135. As with any vaccine, BEXSERO® may not fully protect all of those who are vaccinated.

BEXSERO® multicomponent meningococcal B vaccine (recombinant, adsorbed) is a vaccine for the prevention of meningococcal disease caused by Neisseria meningitidis group B bacteria in individuals from 2 months through 17 years of age. BEXSERO® does not treat or reduce the consequences of meningococcal meningitidis, including meningitis, sepsis, and death. The very common side effects (may affect more than 1 in 10 people) after vaccination with BEXSERO® (reported in all age groups) were pain/tenderness at the injection site, redness at the injection site, swelling of the skin at the injection site, and hardness of the skin at the injection site. In infants and children (up to 10 years of age), fever can occur more frequently when BEXSERO® is given at the same time as routine infant vaccines. Allergic reactions may also occur. Full product information can be found on myg.sk/bexsero. To report an adverse event, please call 1-800-387-7374.

Immunization may not be suitable for everyone and can be associated with adverse effects. Be sure to consult your healthcare provider to see which options are right for you.

Please note: This site does not provide medical advice. The contents of this site are for information purposes only and are not in any way intended to replace or substitute the advice of your healthcare professional. Your own healthcare professional is the best source of information regarding your health. This digital channel is not intended as a means for reporting an adverse event (side effect) or complaint for any GlaxoSmithKline product. To report an adverse event or product complaint, please call 1-800-387-7374. This site is intended for use by Canadian residents only.